Top 5 Stocks to Buy Now
→ My feud with Zohran Mamdani (From Stansberry Research) (Ad)tc pixel
NASDAQ:HSCS

HeartSciences Q3 2025 Earnings Report

HeartSciences logo
$2.75 +0.98 (+55.37%)
Closing price 06/23/2026 04:00 PM Eastern
Extended Trading
$2.59 -0.16 (-5.75%)
As of 08:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

HeartSciences EPS Results

Actual EPS
-$2.57
Consensus EPS
-$2.53
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

HeartSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HeartSciences Announcement Details

Quarter
Q3 2025
Date
3/13/2025
Time
Before Market Opens
Conference Call Date
Thursday, March 13, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

HeartSciences' Q4 2026 earnings is estimated for Thursday, July 23, 2026, based on past reporting schedules, with a conference call scheduled on Friday, July 24, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

HeartSciences' Q3 2025 Press ReleasePress Release
(8-K)
HeartSciences' Q3 2025 Quarterly reportQuarterly report
(10-Q)

HeartSciences Earnings Headlines

HeartSciences (NASDAQ:HSCS) Stock, Earnings Estimates, EPS, And Revenue
 |  benzinga.comhttps://www.benzinga.com/quote/HSCS/earnings
Zcash Miner Fortitude Merging with HeartSciences to Go Public
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/crypto/articles/zcash-miner-fortitude-merging-heartsciences-195641726.html
Now that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)
The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was the trigger. Benedict, who delivered a 279% return on cash in 2025 across a 20-year winning streak, says the listing launched what he calls the 'Final Phase of Elon's Master Plan.' He's identified one specific ticker - not SpaceX, Tesla, or any Elon-affiliated company - that he believes could see billions in inflows as this phase unfolds. He calls it his trade of the year.tc pixel
June 24 at 1:00 AM  |  Brownstone Research (Ad)
HeartSciences Surges on Planned Merger With Zcash Mining Platform Fortitude
June 23 at 11:11 AM  |  quiverquant.comQ
HeartSciences and Fortitude Announce All-Stock Merger Agreement
June 23 at 9:51 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/heartsciences-and-fortitude-announce-all-stock-merger-agreement?utm_source=marketbeat.com&utm_medium=referral
Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets
June 23 at 8:57 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/crypto/articles/fortitude-heartsciences-nasdaq-hscs-announce-113000777.html
See More HeartSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HeartSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartSciences and other key companies, straight to your email.

About HeartSciences

HeartSciences (NASDAQ:HSCS), Inc. (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows. The technology has received regulatory clearance in key markets including the United States and European Union, and the company continues to forge distribution partnerships and develop direct sales channels to broaden its reach among cardiology practices, hospitals and primary care providers. Concurrently, HeartSciences is advancing its research efforts to explore additional clinical applications and refine its diagnostic algorithms.

Headquartered in Bothell, Washington, HeartSciences maintains research and development operations in the United States and collaborates with academic and clinical institutions to validate and expand its platform. As a publicly traded company on the NASDAQ exchange, HeartSciences is led by an executive team and governed by a board of directors committed to driving innovation in non‐invasive cardiovascular diagnostics. Through ongoing product development and strategic partnerships, the company aims to enhance patient outcomes and support clinicians with robust, data‐driven diagnostic tools.

View HeartSciences Profile
Earnings Tools